Emerging research

The IMPACT study followed more than 1,800 BRCA1 and BRCA2 carriers, plus a comparison group of non-carriers, across 20 countries. Everyone got a PSA blood test every year for five years, with a biopsy if the number went above 3.0 ng/mL.^{[1]IMPACT study five-year results, European Urology, 2026}

After five rounds, BRCA2 carriers were diagnosed with clinically significant prostate cancer more than twice as often as non-carriers, 3.1% versus 1.3%. Among the cancers that were found, 65% in BRCA2 carriers were intermediate-unfavorable or high risk, compared with 32% in non-carriers. None had spread at diagnosis. For BRCA1 carriers, the difference in clinically significant cancer wasn't statistically significant, and the authors say screening should be considered rather than recommended outright.^{[1]IMPACT study five-year results, European Urology, 2026}

One limit worth knowing: the study began in 2005, before prostate MRI became part of the diagnostic process, so it tells us about PSA screening and nothing about MRI.

Bottom line: this lines up with the current NCCN guidance of annual PSA screening starting at 40 for BRCA2 carriers.^{[2]NCCN Guidelines Insights 2026: Genetic/Familial High-Risk Assessment} If you carry a mutation and haven't brought it up with your doctor yet, this is a good study to bring with you. Your ages are on the When to screen page.

Multi-cancer early detection tests look for signs of cancer in a blood sample. The best known, Galleri, is designed for adults 50 and older as an add-on to regular screening, not a replacement for it.^{[3]Targeted Oncology: FDA Panel Votes in Favor of Galleri}

The big test of the idea was NHS-Galleri, a trial of about 142,000 people in England. It missed its main goal: adding the test did not significantly reduce the number of stage III and IV cancers (rate ratio 1.03, confidence interval 0.92 to 1.14). Stage IV cancers were numerically lower (0.86), but the interval reaches 1.00, so it isn't counted as a significant drop.^{[4]NHS-Galleri, New England Journal of Medicine, 2026}

In late September an FDA advisory panel voted 7 to 2, with one abstention, that the benefits outweigh the risks. The vote on whether the test works was closer, 6 to 4. The considerations included lower sensitivity for breast and prostate cancers, and the fact that nearly three in four people with a positive signal had at least one invasive procedure. The FDA hasn't made a final decision.^{[3]Targeted Oncology: FDA Panel Votes in Favor of Galleri}

Bottom line: an interesting idea with a benefit that hasn't been shown yet, and less sensitive for two of the cancers male carriers worry about most, breast and prostate. It doesn't replace the screening on the When to screen page.

Aspirin shows up on a lot of cancer prevention lists, so here is what the evidence actually covers. The strongest result comes from Lynch syndrome, a different inherited condition. In the CAPP2 trial, 861 Lynch syndrome carriers took aspirin or a placebo, and long-term follow-up showed a lower rate of colorectal cancer in the aspirin group (hazard ratio 0.65). It showed no effect on the other cancers Lynch syndrome causes.^{[5]CAPP2 trial, The Lancet, 2020}

We didn't find a trial testing aspirin for cancer prevention in people with BRCA mutations. Aspirin also raises the risk of serious bleeding, which is why guidelines treat it as a decision to make with a doctor and not a default.^{[6]U.S. Preventive Services Task Force: Aspirin Use to Prevent Cardiovascular Disease}

Bottom line: a BRCA result alone isn't a reason to start taking aspirin. If the question interests you, bring it to your doctor, who can weigh it against your own bleeding risk.